Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.08.2018 | Case report

Canakinumab

Anaphylactic reaction: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sota J, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology 37: 2233-2240, No. 8, Aug 2018. Available from: URL: http://doi.org/10.1007/s10067-018-4119-x - ItalyCrossRef Sota J, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology 37: 2233-2240, No. 8, Aug 2018. Available from: URL: http://​doi.​org/​10.​1007/​s10067-018-4119-x - ItalyCrossRef
Metadaten
Titel
Canakinumab
Anaphylactic reaction: case report
Publikationsdatum
01.08.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-49908-x

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Thioctic acid

Case report

Lenalidomide